Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
PTC Therapeutics has agreed to acquire the Duchenne muscular dystrophy (DMD) treatment Emflaza from Marathon Pharmaceuticals for $140 million plus potential milestone payments. Marathon won FDA approval for Emflaza on Feb. 9 and immediately stirred controversy by pricing it at $89,000 per year, even though it is based on the generic steroid deflazacort. The firm subsequently paused the launch. PTC, which already markets the DMD treatment ataluren in Europe, says it is finalizing commercialization plans.
This article has been sent to the following recipient: